@article{752830,
      author = {Mita, Monica. and Mita, Alain. and Rowinsky, Eric K.},
      url = {http://library.usi.edu/record/752830},
      title = {mTOR inhibition for cancer therapy past, present and  future / [electronic resource] :},
      abstract = {This book describes the challenges involved in developing  mTOR inhibitors for cancer treatment, starting with an  in-depth examination of their molecular mechanism of  action, with emphasis on the class side-effects, efficacy  and mechanisms of resistance, as well as on promising novel  directions for their development, including novel compounds  and rational combinations with other anti-neoplastic drugs.  Over the last 10 years, inhibitors of mTOR have emerged as  a major class of anticancer drugs. Two rapamycin analogs  are currently approved for the treatment of renal cell  carcinoma, and it is estimated that a variety of other  tumor types could benefit from mTOR inhibition, with  numerous clinical trials (including pivotal registration  trials) already underway. Second-generation small-molecule  inhibitors of the pathway have also shown promise in terms  of their superior tolerability and efficacy and are  undergoing extensive clinical evaluation, with an estimated  30+ compounds currently under evaluation.},
      doi = {https://doi.org/10.1007/978-2-8178-0492-7},
      recid = {752830},
      pages = {1 online resource (vi, 300 pages) :},
}